Recognition determinants of broadly neutralizing human antibodies against dengue viruses

  title={Recognition determinants of broadly neutralizing human antibodies against dengue viruses},
  author={A. Rouvinski and P. Guardado-Calvo and Giovanna Barba-Spaeth and S. Duquerroy and M. Vaney and Carlos Kikuti and M. N. S{\'a}nchez and W. Dejnirattisai and Wiyada Wongwiwat and A. Haouz and C. Girard-Blanc and S. Petres and W. Shepard and P. Despr{\`e}s and F. Arenzana-Seisdedos and P. Dussart and J. Mongkolsapaya and G. Screaton and F. Rey},
  • A. Rouvinski, P. Guardado-Calvo, +16 authors F. Rey
  • Published 2015
  • Biology, Medicine
  • Nature
  • Dengue disease is caused by four different flavivirus serotypes, which infect 390 million people yearly with 25% symptomatic cases and for which no licensed vaccine is available. Recent phase III vaccine trials showed partial protection, and in particular no protection for dengue virus serotype 2 (refs 3, 4). Structural studies so far have characterized only epitopes recognized by serotype-specific human antibodies. We recently isolated human antibodies potently neutralizing all four dengue… CONTINUE READING
    215 Citations
    A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus
    • 22
    Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development
    • 11
    • Highly Influenced
    • PDF
    Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice
    • 19
    • PDF


    Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions
    • 290
    • PDF
    Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins
    • 285
    Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354
    • 115
    • PDF